40% of ischemic strokes never have cause determined. Knowing cause of stroke is critical to patient outcomes and reducing costs.
Ischemia Care's pipeline is based upon over 15 years of publications in major peer reviewed journals with sensitivity and specificty > 95%.
BASE (NCT02014896) is a 600 subject multi site observational prospective study intended to confirm previous findings and lead to a clinically validated test.Read more
Proven management team and advisors (2 IPOs, multiple exits, former Chief of Cardiology at Stanford), KOLs in the field of stroke (author of Stroke Guidelines), strategic support (Affymetrix, Medtronics), and leading stroke centers.Read more
News and Notes
CEO Jeff June presented on the BASE trial as part of the "Ongoing Clinical Trials" session in Nashville, TN.
Over 170 subjects are enrolled in BASE since December 2013
Broadview Ventures leads Ischemia Care Series C.